Phosphoproteomic and Acetylomic Characterization of Colorectal Cancer Cells Treated with Kinase Inhibitors

IF 3.7 Q1 CHEMISTRY, MEDICINAL
Lei Zhao, Mingya Zhang, Jiafu Zhou, Xinglong Jia, Xiaotong Liang, Minjia Tan* and Jun-Yu Xu*, 
{"title":"Phosphoproteomic and Acetylomic Characterization of Colorectal Cancer Cells Treated with Kinase Inhibitors","authors":"Lei Zhao,&nbsp;Mingya Zhang,&nbsp;Jiafu Zhou,&nbsp;Xinglong Jia,&nbsp;Xiaotong Liang,&nbsp;Minjia Tan* and Jun-Yu Xu*,&nbsp;","doi":"10.1021/acsptsci.5c00398","DOIUrl":null,"url":null,"abstract":"<p >Kinase inhibitors have long been studied to be developed into therapeutic drugs or chemical probes, but their off-target effects in phosphoproteomics and acetylomics remain largely unexplored. Here, we provided a systematic molecular response to kinase inhibitors in the colorectal cancer cell line, including the proteomics, phosphoproteomics, and acetylomics. The results provided comprehensive kinase activity perturbations of each kinase inhibitor and presented unique pathway-level biological effects, mitochondrial functional perturbations, and kinase activity changes for inhibitors targeting the same pathway. Furthermore, we discovered the potential protein post-translational modification (PTM) crosstalk between lysine acetylation and protein phosphorylation. The study additionally proposed potential combination treatment strategies. In summary, this study presented in-depth and comprehensive analysis results of kinase inhibitor perturbations on the colorectal cancer cell line at proteomic, phosphoproteomic, and acetylomic landscapes.</p>","PeriodicalId":36426,"journal":{"name":"ACS Pharmacology and Translational Science","volume":"8 9","pages":"3269–3280"},"PeriodicalIF":3.7000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Pharmacology and Translational Science","FirstCategoryId":"1085","ListUrlMain":"https://pubs.acs.org/doi/10.1021/acsptsci.5c00398","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

Abstract

Kinase inhibitors have long been studied to be developed into therapeutic drugs or chemical probes, but their off-target effects in phosphoproteomics and acetylomics remain largely unexplored. Here, we provided a systematic molecular response to kinase inhibitors in the colorectal cancer cell line, including the proteomics, phosphoproteomics, and acetylomics. The results provided comprehensive kinase activity perturbations of each kinase inhibitor and presented unique pathway-level biological effects, mitochondrial functional perturbations, and kinase activity changes for inhibitors targeting the same pathway. Furthermore, we discovered the potential protein post-translational modification (PTM) crosstalk between lysine acetylation and protein phosphorylation. The study additionally proposed potential combination treatment strategies. In summary, this study presented in-depth and comprehensive analysis results of kinase inhibitor perturbations on the colorectal cancer cell line at proteomic, phosphoproteomic, and acetylomic landscapes.

Abstract Image

激酶抑制剂治疗结直肠癌细胞的磷酸蛋白组学和乙酰组学特征
激酶抑制剂长期以来一直被研究开发成治疗药物或化学探针,但其在磷酸化蛋白质组学和乙酰组学中的脱靶作用仍未得到充分的研究。在这里,我们提供了对结直肠癌细胞系中激酶抑制剂的系统分子反应,包括蛋白质组学,磷酸化蛋白质组学和乙酰组学。结果提供了每个激酶抑制剂的全面激酶活性扰动,并呈现出针对同一途径的抑制剂独特的途径水平生物学效应、线粒体功能扰动和激酶活性变化。此外,我们还发现了赖氨酸乙酰化和蛋白质磷酸化之间潜在的蛋白质翻译后修饰(PTM)串扰。该研究还提出了潜在的联合治疗策略。综上所述,本研究从蛋白质组学、磷酸化蛋白质组学和乙酰组学的角度对激酶抑制剂的扰动对结直肠癌细胞系的影响进行了深入和全面的分析。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
ACS Pharmacology and Translational Science
ACS Pharmacology and Translational Science Medicine-Pharmacology (medical)
CiteScore
10.00
自引率
3.30%
发文量
133
期刊介绍: ACS Pharmacology & Translational Science publishes high quality, innovative, and impactful research across the broad spectrum of biological sciences, covering basic and molecular sciences through to translational preclinical studies. Clinical studies that address novel mechanisms of action, and methodological papers that provide innovation, and advance translation, will also be considered. We give priority to studies that fully integrate basic pharmacological and/or biochemical findings into physiological processes that have translational potential in a broad range of biomedical disciplines. Therefore, studies that employ a complementary blend of in vitro and in vivo systems are of particular interest to the journal. Nonetheless, all innovative and impactful research that has an articulated translational relevance will be considered. ACS Pharmacology & Translational Science does not publish research on biological extracts that have unknown concentration or unknown chemical composition. Authors are encouraged to use the pre-submission inquiry mechanism to ensure relevance and appropriateness of research.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信